132 related articles for article (PubMed ID: 27730744)
1. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
Sepehri S; Saghaie L; Fassihi A
Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744
[TBL] [Abstract][Full Text] [Related]
2. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
3. A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.
Pang W; Wang RR; Gao YD; Yang LM; Sun Y; Huang JF; Tien P; Zheng YT
J Biomol Screen; 2011 Feb; 16(2):221-9. PubMed ID: 21297108
[TBL] [Abstract][Full Text] [Related]
4. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
5. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
6. Potential HIV-1 fusion inhibitors mimicking gp41-specific broadly neutralizing antibody 10E8: In silico discovery and prediction of antiviral potency.
Andrianov AM; Kashyn IA; Tuzikov AV
J Bioinform Comput Biol; 2018 Apr; 16(2):1840007. PubMed ID: 29439644
[TBL] [Abstract][Full Text] [Related]
7. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
9. High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.
Jin BS; Lee WK; Ahn K; Lee MK; Yu YG
J Biomol Screen; 2005 Feb; 10(1):13-9. PubMed ID: 15695339
[TBL] [Abstract][Full Text] [Related]
10. Designing a soluble near full-length HIV-1 gp41 trimer.
Gao G; Wieczorek L; Peachman KK; Polonis VR; Alving CR; Rao M; Rao VB
J Biol Chem; 2013 Jan; 288(1):234-46. PubMed ID: 23184960
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.
Allen WJ; Yi HA; Gochin M; Jacobs A; Rizzo RC
Bioorg Med Chem Lett; 2015 Jul; 25(14):2853-9. PubMed ID: 26013847
[TBL] [Abstract][Full Text] [Related]
12. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Liu S; Jiang S
Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
[TBL] [Abstract][Full Text] [Related]
13. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
[TBL] [Abstract][Full Text] [Related]
14. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
[TBL] [Abstract][Full Text] [Related]
15. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
16. Gp41 inhibitory activity prediction of theaflavin derivatives using ligand/structure-based virtual screening approaches.
Mostashari-Rad T; Saghaei L; Fassihi A
Comput Biol Chem; 2019 Apr; 79():119-126. PubMed ID: 30785021
[TBL] [Abstract][Full Text] [Related]
17. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
McGee TD; Yi HA; Allen WJ; Jacobs A; Rizzo RC
Bioorg Med Chem Lett; 2017 Jul; 27(14):3177-3184. PubMed ID: 28558972
[TBL] [Abstract][Full Text] [Related]
18. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
Steffen I; Pöhlmann S
Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
[TBL] [Abstract][Full Text] [Related]
19. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]